CDK4 and breast carcinoma: Taken together, the lack of targeted treatment options and the failure to achieve locoregional control of aggressive breast cancers — including TNBC — represents a clear unmet clinical need, but our understanding of the potential of combined CDK4/6 inhibitor therapy and radiotherapy in TNBC remains insufficient.